Sagent Pharmaceuticals, Inc. (SGNT) Misses Q1 EPS by 2c

May 10, 2012 5:01 PM EDT Send to a Friend
Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) reported Q1 EPS of ($0.30), $0.02 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $38.3 million versus the consensus estimate of $42.31 million.

For earnings history and earnings-related data on Sagent Pharmaceuticals, Inc. (SGNT) click here.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings

Add Your Comment